In this episode, Li Yan, the Managing Director of the US Chinese Anti-Cancer Association and the former CMO of Brii Biosciences, talks about the cultural and job differences in the biotech field. He also discusses clinical trials, new cancer drugs, and how U.S. and Chinese scientists collaborate.

Li highlights how key mentorship is, the need for clear communication in clinical studies, and ways to handle cross-cultural work challenges.

Here's what you're in for:

01:14 Professional Background and Work at Yonsei University

03:53 Journey from China to the U.S.

07:14 COVID-19 Research and Clinical Trials

16:12 Challenges in Clinical Trials and Biotech Industry

23:22 Cultural Differences and Leadership in Biotech

25:52 U.S.-China Anti-Cancer Collaboration

33:12 Mentorship and Career Advice

About Li Yan

Li Yan, MD, PhD, Managing Director, US Chinese Anti-Cancer Association; Adjunct Professor at Yonsei University Medical School. He was the former CMO of Brii Biosciences and is now currently preparing his next venture with a stealth start-up.

Li originally studied medicine in Beijing and then moved to Kansas to begin his oncology and clinical career in the US. From there, he joined J&J, Merck, and GSK before jumping into the fast-moving world of biotech.

Connect with Li Yan:

LinkedIn: https://www.linkedin.com/in/li-yan-88b5b46/

About Charles

Charles Spence leads Discera, a leading recruitment firm specializing in the biopharma industry.

He graduated with a biomedical degree, has worked in hospitals (including translation work in Seoul, South Korea), and also spent years doing diabetes research. After doing research and travel, a career in business and science felt the most appropriate.

In 2023, Charles decided to launch his firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East Coast and DACH.

Connect with Charles:

LinkedIn: https://www.linkedin.com/in/charles-spence-clinical/

Website: https://www.discera-search.com/